Aurobindo Pharma has reported consolidated net sales of Rs 4567.6 crore in FY 11-12 as against Rs 4,125.9 crore in FY 10-11 showing a 10.7 per cent increase. The consolidated net operating income was reported at Rs 4627.4 crore in FY 11-12 as against Rs 4,381.5 crore in FY 10-11, showing an increase of 5.6 per cent.
However, the company’s operating profit (EBIDTA) was reported at Rs 610.1 crore in FY 11-12, against Rs 963.3 crore in FY 10-11, a decrease of 36.7 per cent. Profit Before Tax (PBT) was reported at Rs 331.5 crore in FY 11-12, against Rs 751.0 in FY 10-11, a decrease of 55.9 per cent.
Rationalising the sizable dip in profits, N Govindarajan, CEO, Aurobindo Pharma said, “We have concluded a challenging year highlighted by full impact of the US FDA alert on our Unit 6 Cephalosporin manufacturing facility, high cost of materials, inflation and notional loss on restatement of foreign currency borrowings.”
He expects that planned launches of new products and increasing market shares of the company’s existing products, supported by the growing business of high value APIs on the regulated market will improve the company’s performance going forward.
The profitability during the year has also been impacted by higher staff costs (1.4 per cent to net sales) mainly due to new hires in European countries and Aurolife, US.
The board has recommended final dividend @100 per cent on the equity share capital of the company i.e Re 1 per share subject to approval of shareholders.
EP News Bureau — Mumbai
- Advertisement -
